Author

Johan Sandzén

Observed names: J. Sandzén, Johan Sandzen

Institution: Karlstad Central Hospital

Observed institution: Karlstad Central Hospital

ORCID: 0009-0005-8044-3817

Observed ORCID: 0009-0005-8044-3817

OpenAlex ID: A5027793133

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

2024 · Bram De Laere, Alessio Crippa, et al. · Nature Medicine · 33

Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

2022 · Fredrik Liedberg, Sofia Kjellström, et al. · Scandinavian Journal of Urology · 20

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial

2025 · Alessio Crippa, Bram De Laere, et al. · European Urology Oncology · 11

1619P Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial

2024 · A. Kristiansen, B. Sautois, et al. · Annals of Oncology · 3

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

2023 · Karin Holmsten, Johanna Eknert, et al. · Clinical Genitourinary Cancer · 2

REASSURE observational study of radium-223 (Ra-223): First interim results by prior/concomitant treatment (Tx) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) enrolled in Europe

2018 · J. Logue, M. Schostak, et al. · European Urology Supplements · 2

LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

2023 · H. Grönberg, J. Lindberg, et al. · Annals of Oncology · 1

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

2024 · Bram De Laere, Alessio Crippa, et al. · Nature Medicine

Works count: 8

Citation count: 72

H-index: 3

I10-index: 3